Remember
 
 
At SpeculatingStocks You Can Discover Stocks, Post Anonymously, and React to Posts. Login is Optional.
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap



































































380.52M









































































































Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




10/18/2017: $ABBV AbbVie and Harpoon Therapeutics have entered an immuno-oncology research collaboration to incorporate Harpoon's tri-specific T-cell activating construct (TriTAC) platform with AbbVie's research-stage immuno-oncology targets to develop novel cancer therapeutics. -- Go to this Pulse Post



10/18/2017: $MRK Merck presented updated overall survival findings from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA in patients with non-small cell lung cancer whose tumors express high levels of PD-L1. -- Go to this Pulse Post



10/17/2017: $SYRS Syros Pharmaceuticals to present new data showing the relationship between SY-1365's PK and PD and anti-tumor activity in mouse xenograft models of AML and triple negative breast cancer at AACR-NCI-EORTC Conference Oct 26-30. -- Go to this Pulse Post



10/16/2017: $SYRS Syros Pharmaceuticals to present new data showing the relationship between SY-1365's PK and PD and anti-tumor activity in mouse xenograft models of AML and triple negative breast cancer at AACR-NCI-EORTC Conference Oct 26-30. -- Go to this Pulse Post



10/16/2017: $CLSN Celsion announced publication of review of ThermoDox for the treatment of primary liver cancer in medical journal Clinical Cancer Research. -- Go to this Pulse Post



10/10/2017: $CLVS Clovis Oncology has submitted sNDA to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. -- Go to this Pulse Post



10/09/2017: $CLVS Clovis Oncology has submitted sNDA to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. -- Go to this Pulse Post



10/09/2017: $CGEN Compugen disclosed new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy. -- Go to this Pulse Post



10/06/2017: $KTOV Kitov Pharmaceuticals ACQUIRES additional 27% stake in TyrNovo, a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders. -- Go to this Pulse Post



10/02/2017: $GALE Galena Biopharma's merger partner Sellas Life Sciences entered into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck (MRK. -- Go to this Pulse Post



09/28/2017: $RHHBY Roche Hldg announced the expanded use of the VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer and metastatic urothelial carcinoma in CE markets where TECENTRIQ is approved. -- Go to this Pulse Post



09/27/2017: $MATN Mateon Therapeutics terminated FOCUS study in ovarian cancer and restructuring to prioritize OXi4503 for AML. -- Go to this Pulse Post



09/26/2017: $MATN Mateon Therapeutics terminated FOCUS study in ovarian cancer and restructuring to prioritize OXi4503 for AML. -- Go to this Pulse Post



09/26/2017: $GNCA Genocea Biosciences announced strategic shift to immuno-oncology/development of neoantigen cancer vaccines; corporate restructuring and exploration of strategic alternatives for GEN-003 - halted. -- Go to this Pulse Post



09/26/2017: $CSBR Champions Oncology announced a $2M award from the National Cancer Institute to develop and evaluate prostate cancer PDX. -- Go to this Pulse Post



09/25/2017: $ICAD iCAD will present new clinical data supporting the use of the Xoft AxxentElectronic Brachytherapy System for the treatment of nonmelanoma skin cancer and early-stage breast cancer during the 2017 Astro Meeting. -- Go to this Pulse Post



09/25/2017: $VRAY ViewRay launched a multi-center prospective clinical trial for locally advanced unresectable pancreatic cancer using MRIdian; first initiative based on retrospective study that suggests potential for significantly prolonged survival. -- Go to this Pulse Post



09/21/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/20/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/19/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/18/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/15/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/14/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/13/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/12/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/11/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/08/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/07/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/06/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/05/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/04/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



09/01/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post